Palliative Care for Blood Cancers During Cellular Therapy
This study is testing if a special type of care called palliative care (PEACE) can improve the quality of life and experiences for people with blood cancers like Lymphoma, Leukemia, or Multiple Myeloma. You might be eligible if you are 18 or older, have a blood cancer, and are receiving a specific type of treatment called autologous adoptive cellular therapy (ACT) at MGH. The study aims to see how many eligible people enroll in the PEACE intervention. The current status of the study is unclear, but it plans to enroll about 90 people.
- Study design
- This is a randomized study, meaning participants are assigned to a group by chance, with about 90 participants planned.
- What's involved
- Participation in this research study is expected to last for up to 2 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Patrick C Johnson, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Percentage of Eligible Participants Enrolled to Palliative Care Intervention (PEACE) (Feasibility)1 day
Defined as at least 60% of eligible participants enrolling in the study, and among those enrolled and randomized to PEACE, 80% receiving PEACE as intended.